S

South Oklahoma Heart Research, LLC | Oklahoma City, OK

Research site
(Unclaimed)
Location
5224 E. I-240 Service Road, Suite 202, Oklahoma City, Oklahoma, United States of America

Site insights

Top conditions

Top treatments

Bococizumab
Apixaban
Ziltivekimab
BELVIQ
Iron
CER-001
Milvexian
Cholesterol
Inclisiran
Finerenone

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 20 total trials
Locations recently updated

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab
Locations recently updated

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Other: Placebo
Drug: Milvexian

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Placebo
Drug: Apixaban Placebo

The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that lo...

Enrolling
Heart Failure
Drug: Open-label, PK Cohort: ponsegromab medium dose
Drug: Open-label, PK Cohort: ponsegromab low dose

Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneousl...

Invitation-only
Heart Failure
Other: Sham-Control
Device: Alleviant ALV1 System

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Begins enrollment this month
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Placebo
Drug: Ziltivekimab
Locations recently updated

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of MK-0616, an oral proprotein convertase subtilisin/kexin type 9...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: MK-0616

The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic...

Enrolling
Heart Failure
Other: Placebo
Drug: BMS-986435

The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiov...

Active, not recruiting
Heart Failure
Other: Placebo
Drug: Finerenone (BAY94-8862)

Trial sponsors

Pfizer logo
Bayer logo
J
Novo Nordisk logo
A
American Regent logo
Arrowhead Pharmaceuticals logo
Bristol-Myers Squibb (BMS) logo
C
Eisai logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems